Voriconazole use for endemic fungal infections

Alison Freifeld, Laurie Proia, David Andes, Larry M. Baddour, Janis Blair, Brad Spellberg, Sandra Arnold, Arnold Lentnek, L. Joseph Wheat

Research output: Contribution to journalArticle

89 Scopus citations


In a retrospective review of 24 patients with histoplasmosis, blastomycosis, or coccidioidomycosis treated with voriconazole (most for salvage therapy), the outcome was favorable (improved or stable) for 22 (95.8%) within 2 months of starting voriconazole and for 20 (83.3%) at the last follow-up. Prospective studies are required to determine its role in the treatment of endemic mycoses.

Original languageEnglish (US)
Pages (from-to)1648-1651
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Issue number4
StatePublished - Apr 2009

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Voriconazole use for endemic fungal infections'. Together they form a unique fingerprint.

  • Cite this

    Freifeld, A., Proia, L., Andes, D., Baddour, L. M., Blair, J., Spellberg, B., Arnold, S., Lentnek, A., & Wheat, L. J. (2009). Voriconazole use for endemic fungal infections. Antimicrobial Agents and Chemotherapy, 53(4), 1648-1651. https://doi.org/10.1128/AAC.01148-07